• Recruiting

NCT03839459: Phase 2: Denosumab for Smoldering Multiple Myeloma

Updated: May 23


NCT03839459: Phase 2: Denosumab for Smoldering Multiple Myeloma


denosumab

Denosumab for Smoldering Multiple Myeloma


This study will assess the safety and tolerability of denosumab in smoldering multiple myeloma subjects as well to see if denosumab can reduce subjects' risk of getting multiple myeloma.


Sponsor

University of Rochester


Collaborator

Amgen


Location

New York

 

ClinicalTrials.gov Identifier: NCT03839459


Official Title: Denosumab for Smoldering Multiple Myeloma

First Posted : February 15, 2019


https://clinicaltrials.gov/ct2/show/NCT03839459

 

Drug: Denosumab


Denosumab: National Cancer Institute

XGEVA (denosumab) injection

 

Location

United States, New York





Posts Archive